Conexiant’s news site is now MDSpire News. Learn more
Advertisement
CDC estimates 9.7 million infections annually from AMR threats
“These numbers are alarming by any measure but are particularly sobering when infectious diseases physicians connect real patients with these statistics."
To summarize CDC’s 2026 Antimicrobial Resistance Threats Report, including estimated U.S. infection and death burdens, changes in threat classifications and IDSA’s call for federal action.
Approach:
: The report, released October 27, 2026, used 2023 data and updated analytical methods.
: CDC identified 19 bacterial and fungal threats classified as urgent, serious or concerning, plus 6 watch-list pathogens whose full U.S. impact remains uncertain.
: Threat assessment factors included clinical and economic impact, infection incidence, projected changes over 5 years, transmissibility, preventability and treatment availability.
Key Findings:
CDC estimated 9.7 million infections and 50,800 deaths annually in the United States from the bacterial and fungal pathogens covered by the report. More than 9.3 million infections and more than 39,000 deaths involved drug-resistant pathogens.
The higher totals include Clostridioides difficile, which is not typically drug resistant. Its inclusion reflects the contributions of antibiotic use and pathogen transmission to both C. difficile infections and antimicrobial resistance.
Four pathogens were classified as urgent threats: Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
C. difficile moved from the urgent to the serious category. CDC attributed the change partly to improved infection prevention, particularly in health care settings, where infections have declined since 2011.
Drug-resistant Neisseria meningitidis was added to the serious category. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria were added to the watch list.
Seven bacterial threats commonly associated with health care caused more than 42,000 deaths in 2023 and accounted for nearly $12 billion in health care costs.
Estimates for drug-resistant group A Streptococcus and clindamycin-resistant group B Streptococcus were expanded to include noninvasive as well as invasive infections.
Interpretation:
The report describes a substantial burden from antimicrobial resistance and C. difficile. IDSA President Wendy S. Armstrong, MD, FIDSA, emphasized the consequences for patients, hospital stays, health care costs and the ability to safely provide procedures such as chemotherapy, transplantation and joint replacement.
Limitations:
The estimates use 2023 data rather than measurements from the report’s publication year.
CDC cautioned against direct comparisons with previous threat reports because data sources and methods changed substantially for all pathogens except C. auris.
The full U.S. impact of watch-list pathogens remains uncertain.
Conclusion:
Armstrong urged Congress to pass the bipartisan PASTEUR Act to encourage development of new antimicrobial drugs and support antimicrobial stewardship. The report updates threat classifications and burden estimates while emphasizing the need to account for methodological changes when interpreting comparisons with earlier reports.